Silexion Therapeutics Corp

1. 1

   Authorized Share Capital Increase Proposal

   ManagementBoard: FOR

   Approve an increase in the Company’s authorized share capital by 175,000,000 ordinary shares, from 15,900,000 shares with a total par value of US$2,146,500 to 190,900,000 shares with a total par value of US$25,771,500, subject to proportionate adjustment if the reverse share split is approved.

   More detail

   Proposal 1 asks shareholders to increase Silexion’s authorized ordinary shares by 175 million, from 15.9 million to 190.9 million, while keeping the stated par value at $0.135 per share before any reverse-split adjustment. The proposal itself does not issue shares immediately, but it would create a substantially larger pool available for future issuance. Management says the additional capacity is necessary to preserve compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of shareholders’ equity under the Nasdaq Capital Market Equity Standard. The Company reports that its available authorized share capital is constrained by outstanding warrants, its ATM program, potential conversion of the Moringa sponsor note, equity plans, and possible public offerings. Management also expects materially higher expenditures as it advances Phase 2/3 clinical trials for SIL204 and therefore seeks financing flexibility for working capital and development activities. The expanded authorization could also support acquisitions or other business-development transactions involving complementary assets and could facilitate debt conversion or equity compensation. The filing expressly acknowledges that subsequent issuances could significantly dilute existing holders, reduce per-share equity, pressure the trading price, and potentially create takeover-related concerns, although the Board says it intends to manage the reserve carefully. The increase is coordinated with Proposal 2 because the authorized share count and par value would be adjusted proportionately if a reverse split is implemented. The Board unanimously recommends voting FOR, principally because it views Nasdaq compliance and access to capital as critical to the Company’s clinical program and shareholder value.

2. 2

   Reverse Share Split Proposal

   ManagementBoard: FOR

   Authorize the Board, subject to shareholder approval of a specific ratio presented at the meeting, to effect a reverse split of all issued and unissued ordinary shares at a ratio between 1-for-7 and 1-for-15, with the exact ratio selected based on market conditions and the Company’s share price.

   More detail

   Proposal 2 asks shareholders to approve a reverse split of all issued and unissued ordinary shares at a ratio between 1-for-7 and 1-for-15. The Board will select and present the specific ratio at the meeting based on market conditions and the trading price immediately before the meeting, and it retains discretion not to implement the split after approval. Management’s principal objective is to address Nasdaq Listing Rule 5550(a)(2), which requires a continuing minimum bid price of $1.00 per share. Silexion has already completed 1-for-9, 1-for-15, and 1-for-10 reverse splits, most recently on May 28, 2026, and warns that another failure to maintain the minimum bid price could lead to immediate delisting proceedings after 30 consecutive trading days below $1.00. Management also argues that a higher share price may improve access to investors and financing needed for the SIL204 Phase 2/3 clinical trials. The split would proportionately reduce the number of issued and authorized shares and increase the par value, while generally preserving each holder’s percentage ownership. Outstanding warrants, options, and equity-plan share limits would be adjusted proportionately, and fractional shares would be rounded up or down rather than paid in cash. The filing cautions that the market price may not rise proportionately or remain elevated, and that the split could reduce liquidity, increase odd-lot holdings, and intensify volatility. Because the Company remains a small-cap biotechnology issuer with substantial financing needs and a history of repeated reverse splits, the proposal carries meaningful execution and market-risk considerations. The Board unanimously recommends voting FOR the proposal because it believes the split is necessary or strategically useful to protect Nasdaq listing compliance and support future capital raising.

Upcoming shareholder meetings at Silexion Therapeutics Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Silexion Therapeutics Corp 2026 special meeting?

Silexion Therapeutics Corp (SLXN) holds its 2026 special shareholder meeting on Wednesday, September 9, 2026.

What is the record date for the Silexion Therapeutics Corp 2026 meeting?

The record date for the Silexion Therapeutics Corp 2026 meeting is Monday, August 24, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Silexion Therapeutics Corp's 2026 meeting?

The board is presenting 7 director nominees at the Silexion Therapeutics Corp 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Silexion Therapeutics Corp 2026 meeting?

Shareholders will vote on 2 proposals at the Silexion Therapeutics Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.